Skip to main content

Table 3 Adverse Events

From: Epinephrine delivery via EpiPen® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances

 

Mid-AL thigh

Distal-AL thigh

Epinephrine via EpiPen (N = 35)

Epinephrine via IM syringe (N = 35)

Saline via IM syringe (N = 35)

Epinephrine via EpiPen (n = 23)

Total AEs, n

27

25

7

15

AEs considered related to treatment (> 3% in any treatment group), n (%)a

Palpitations

6 (17.1)

4 (11.4)

0

7 (30.4)

Feeling abnormal

4 (11.4)

2 (5.7)

0

2 (8.7)

Feeling hot

3 (8.6)

1 (2.9)

0

0

Tremor

3 (8.6)

1 (2.9)

0

1 (4.3)

Headache

1 (2.9)

2 (5.7)

1 (2.9)

0

Limb discomfort

1 (2.9)

1 (2.9)

0

1 (4.3)

Myalgiab

0

2 (5.7)

0

0

  1. AE adverse event, AL anterolateral, EpiPen EpiPen Auto-Injector, IM intramuscular
  2. aAEs are listed in order of incidence
  3. bMyalgia was reported only in thigh muscle